



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of : **Confirmation No. 7724**
Brian A. JOHNS et al. : Attorney Docket No. 2008_1236 (NEW)
Serial No. 10/597,902 : Group Art Unit 1625
Filed August 11, 2006 : Examiner David K. O'Dell

2-OXONAPHTHYRIDINE-3-CARBOXAMIDES
HIV INTEGRASE INHIBITORS (AS AMENDED) **Mail Stop: Amendment**

SUBMISSION OF NEW POWERS OF ATTORNEY

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Submitted herewith are two New Powers of Attorney and Correspondence Address
Indication Form executed by an authorized representative of the Assignees.

Please change the correspondence address and direct all future communications to the
attorney and law firm indicated in the documents.

Respectfully submitted,

Brian A. JOHNS et al.

By: Warren M. Cheek
Warren M. Cheek
Registration No. 33,367
Attorney for Applicants

WMC/dlk
Washington, D.C. 20006-1021
Telephone (202) 721-8200
Facsimile (202) 721-8250
September 22, 2008



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In-re application of : **Confirmation No. 7724**
Brian A. JOHNS et al. : Attorney Docket No. 2008_1236 (New)
Serial No. 10/597,902 : Group Art Unit 1625
Filed August 11, 2006 : Examiner David K. O'Dell
HIV INTEGRASE INHIBITORS : **Mail Stop: Amendment**

NEW POWER OF ATTORNEY

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Shionogi & Co., Ltd., Assignee of partial right, title and interest in and to the above-referenced U.S. application by virtue of an Assignment recorded at Reel 016129, Frame 0051 on April 21, 2005, hereby appoints Warren M. Cheek, Jr., Esq., Reg. No. 33367, Michael R. Davis, Reg. No. 25134, Matthew M. Jacob, Reg. No. 25154, Nils E. Pedersen, Reg. No. 33145, Charles R. Watts, Reg. No. 33142, Michael S. Huppert, Reg. No. 40268, Jeffrey R. Filipek, Reg. No. 41471, Douglas W. Hahm, Reg. No. 44142 and David M. Ovedovitz, Reg. No. 45336 constituting the firm of WENDEROTH, LIND & PONACK, L.L.P. Suite 800, 2033 K Street, N.W., Washington, D.C. 20006, with full power to prosecute said application, to make alterations and amendments therein, to receive the patent, and to transact all business in the Patent and Trademark Office in connection therewith.

Please immediately change the correspondence address and send all future communications to:

Warren M. Cheek, Jr.
WENDEROTH, LIND & PONACK, L.L.P.
2033 K Street, N.W., Suite 800
Washington, D.C. 20006
Facsimile No. (202) 721-8250
Telephone No. (202) 721-8200

The undersigned is authorized to execute this document on behalf of the Assignee.

SHIONOGI & CO., LTD.

By: 
Isao TESHIROGI

Title: President and Representative Director

Date: September 17, 2008



PTO/SB/81 (06-04)

Approved for use through 12/31/2008. OMB 0651-0035

U.S. Patent and Trademark Office: US DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control numb

POWER OF ATTORNEY and CORRESPONDENCE ADDRESS INDICATION FORM	Application Number	10/597902
	Filing Date	August 11, 2006
	First Named Inventor	JOHNS, Brian
	Title	HIV Integrase Inhibitors
	Art Unit	
	Examiner Name	
	Attorney Docket Number	PR60567US

I hereby revoke all previous powers of attorney given in the above-identified application.

I hereby appoint:

☒ Practitioners associated with the Customer Numbers. 000513

Or

☐ Practitioner(s) named below:

Name	Registration Number

As my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith.

Please recognize or change the correspondence address for the above-identified application to:

☐ The address associated with the above-mentioned Customer Number: 000513

Or

☒ The address associated with Customer Number

Or

☐ Firm or Individual Name:

Address:

Address:

City:

State:

Zip:

Country:

Telephone:

Fax:

I am the:

☐ Applicant/Inventor:*partial*☒ Assignee or record of the ~~entire~~ interest. See 37 CFR 3.71.

Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96)

SIGNATURE of Applicant or Assignee of RecordSignature: *Robert H. Brink*Date: *25 August 2008*

Name: Robert H. Brink

Telephone: (919) 483-3323

Title and Company: Attorney, SmithKline Beecham Corporation

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required.

Submit multiple forms if more than one signature is required, see below*.

☐ *Total of: forms are submitted.

This collection of information is required by 37 CFR 1.31 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is essential to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commission for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PTO/SB/96 (12-05)

Approved for use through 7/31/2006. OMB 0651-0035

U.S. Patent and Trademark Office: US DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control numb

STATEMENT UNDER 37 CFR 3.73(b)Applicant/Patent Owner: **SMITHKLINE BEECHAM CORPORATION**Application No./Patent No.: **10/597902**Filed/Issue Date: **August 11, 2006**Entitled: **HIV Integrase Inhibitors****SmithKline Beecham Corporation, a corporation, states that it is:**1. ☒ the assignee of the ~~entire~~ right, title, and interest; or2. ☐ an assignee of less than the entire right, title and interest.

The extent (by percentage) of its ownership interest is _____% in the patent application/patent identified above by virtue of either;

A. ☒ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel 116129, Frame 0043, or for which a copy thereof is attached.

OR

B. ☐ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:1. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.2. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.3. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.☐ Additional documents in the chain of title are listed on a supplemental sheet.☐ Copies of assignments or other documents in the chain of title are attached.

[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

Robert H. Brink
Signature26 August 2008
DateRobert H. Brink
Printed or Typed Name(919) 483-3323
Telephone NumberAttorney
Title

This collection of information is required by 37 CFR 1.31 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is essential to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commission for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.